|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Stephen R. Davis||CEO & Director||1,36M||7,98M||1961|
|Dr. Srdjan R. Stankovic||Pres||1,23M||S.O.||1957|
|Ms. Elena H. Ridloff C.F.A., CFA||Exec. VP & CFO||689,09k||1,22M||1980|
|Mr. Austin D. Kim||Exec. VP, Gen. Counsel & Sec.||700,8k||480,9k||1964|
|Mr. Michael J. Yang||Exec. VP & Chief Commercial Officer||810,41k||1,62M||1962|
|Mr. James K. Kihara||VP, Corp. Controller & Principal Accounting Officer||S.O.||S.O.||1980|
|Mr. Bob Mischler||Sr. VP of Strategy & Technology Operations||S.O.||S.O.||S.O.|
|Dr. Eliseo Oreste Salinas||Sr. VP, Chief Scientific Officer & Head of External Innovation||S.O.||S.O.||1956|
|Mr. Mark C. Johnson||VP of Investor Relations||S.O.||S.O.||S.O.|
|Mr. Ryan E. Brown||Chief Compliance Officer & VP||S.O.||S.O.||S.O.|
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
L’ISS Governance QualityScore de ACADIA Pharmaceuticals Inc. en date du 31 octobre 2019 est 9. Les scores principaux sont Audit : 2; Société : 7; Droits des actionnaires : 8; Compensation : 10.